Press Releases

Feb 13, 2025, 07:30 ET Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel ‘next generation’ selective MC4R long-acting peptide and an oral small molecule Multiple clinical trials targeted in calendar year 2025 For the treatment of general obesity, […]

Feb 10, 2025, 16:00 ET CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

Feb 07, 2025, 08:00 ET CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor

Feb 06, 2025, 07:30 ET Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of its

Jan 28, 2025, 07:30 ET Obesity programs: Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Topline results expected 1Q calendar year 2025 General obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesity Multiple clinical trials targeted to commence 2H calendar year 2025 with long-acting MC4R peptide and/or MC4R

Dec 19, 2024, 07:30 ET Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy at 6 months 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr) 71% of patients achieved improved or stabilized estimated glomerular filtration rate

Dec 16, 2024, 07:30 ET CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the “inducement agreement”) with

Nov 25, 2024, 07:30 ET Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concerns Preclinical data demonstrated that oral PL8177 caused diseased colons to move towards a healthy state and to resolve damaging inflammation Data

Nov 14, 2024, 07:30 ET Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Patient enrollment completed October 2024 Topline results expected 1Q calendar year 2025 Multiple clinical trials targeted in calendar year 2025

Nov 08, 2024, 09:57 ET CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its